Salivary Gland Mucoepidermoid Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma that arises from the salivary glands. It is the most common primary carcinoma of the salivary glands and usually presents as a firm and painless mass. It is characterized by the presence of epidermoid cells, mucus producing cells, and cells of intermediate type. The majority of cases have a favorable outcome. 
Salivary gland mucoepidermoid carcinomas most frequently harbor alterations in TP53, CDKN2A, PIK3CA, RECQL4, and HRAS .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in salivary gland mucoepidermoid carcinoma .
There is 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains salivary gland mucoepidermoid carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for salivary gland mucoepidermoid carcinoma clinical trials .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most common interventions in salivary gland mucoepidermoid carcinoma clinical trials.
Significant Genes in Salivary Gland Mucoepidermoid Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland mucoepidermoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland mucoepidermoid carcinoma trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.